BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12239297)

  • 1. Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.
    Cohen WM; Bianco A; Connan F; Camoin L; Dalod M; Lauvau G; Ferriès E; Culmann-Penciolelli B; van Endert PM; Briand JP; Choppin J; Guillet JG
    J Virol; 2002 Oct; 76(20):10219-25. PubMed ID: 12239297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.
    Brander C; Yang OO; Jones NG; Lee Y; Goulder P; Johnson RP; Trocha A; Colbert D; Hay C; Buchbinder S; Bergmann CC; Zweerink HJ; Wolinsky S; Blattner WA; Kalams SA; Walker BD
    J Virol; 1999 Dec; 73(12):10191-8. PubMed ID: 10559335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
    Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
    Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.
    Yokomaku Y; Miura H; Tomiyama H; Kawana-Tachikawa A; Takiguchi M; Kojima A; Nagai Y; Iwamoto A; Matsuda Z; Ariyoshi K
    J Virol; 2004 Feb; 78(3):1324-32. PubMed ID: 14722287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential processing of HLA A2-restricted HIV type 1 cytotoxic T lymphocyte epitopes.
    Sewell AK; Booth BL; Cerundolo V; Phillips RE; Price DA
    Viral Immunol; 2002; 15(1):193-6. PubMed ID: 11952141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
    Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
    J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
    J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.
    Masemola AM; Mashishi TN; Khoury G; Bredell H; Paximadis M; Mathebula T; Barkhan D; Puren A; Vardas E; Colvin M; Zijenah L; Katzenstein D; Musonda R; Allen S; Kumwenda N; Taha T; Gray G; McIntyre J; Karim SA; Sheppard HW; Gray CM;
    J Immunol; 2004 Oct; 173(7):4607-17. PubMed ID: 15383595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
    Goulder PJ; Brander C; Annamalai K; Mngqundaniso N; Govender U; Tang Y; He S; Hartman KE; O'Callaghan CA; Ogg GS; Altfeld MA; Rosenberg ES; Cao H; Kalams SA; Hammond M; Bunce M; Pelton SI; Burchett SA; McIntosh K; Coovadia HM; Walker BD
    J Virol; 2000 Jun; 74(12):5679-90. PubMed ID: 10823876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais.
    Bond KB; Sriwanthana B; Hodge TW; De Groot AS; Mastro TD; Young NL; Promadej N; Altman JD; Limpakarnjanarat K; McNicholl JM
    AIDS Res Hum Retroviruses; 2001 May; 17(8):703-17. PubMed ID: 11429111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.
    Kan-Mitchell J; Bisikirska B; Wong-Staal F; Schaubert KL; Bajcz M; Bereta M
    J Immunol; 2004 May; 172(9):5249-61. PubMed ID: 15100263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
    Klein MR; van der Burg SH; Hovenkamp E; Holwerda AM; Drijfhout JW; Melief CJ; Miedema F
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2191-201. PubMed ID: 9747728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of human cytotoxic T cells with HIV-1-derived peptides presented by recombinant HLA-A2 peptide complexes.
    Walter JB; Brander C; Mammen M; Garboczi DN; Kalams SA; Whitesides GM; Walker BD; Eisen HN
    Int Immunol; 1997 Mar; 9(3):451-9. PubMed ID: 9088983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
    Allen TM; Altfeld M; Yu XG; O'Sullivan KM; Lichterfeld M; Le Gall S; John M; Mothe BR; Lee PK; Kalife ET; Cohen DE; Freedberg KA; Strick DA; Johnston MN; Sette A; Rosenberg ES; Mallal SA; Goulder PJ; Brander C; Walker BD
    J Virol; 2004 Jul; 78(13):7069-78. PubMed ID: 15194783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.
    Tenzer S; Wee E; Burgevin A; Stewart-Jones G; Friis L; Lamberth K; Chang CH; Harndahl M; Weimershaus M; Gerstoft J; Akkad N; Klenerman P; Fugger L; Jones EY; McMichael AJ; Buus S; Schild H; van Endert P; Iversen AK
    Nat Immunol; 2009 Jun; 10(6):636-46. PubMed ID: 19412183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
    Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
    J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide.
    Barouch D; Davenport M; McMichael A; Reay P
    Int Immunol; 1995 Oct; 7(10):1599-605. PubMed ID: 8562505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
    Gray CM; Lawrence J; Schapiro JM; Altman JD; Winters MA; Crompton M; Loi M; Kundu SK; Davis MM; Merigan TC
    J Immunol; 1999 Feb; 162(3):1780-8. PubMed ID: 9973442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.
    Lucchiari-Hartz M; van Endert PM; Lauvau G; Maier R; Meyerhans A; Mann D; Eichmann K; Niedermann G
    J Exp Med; 2000 Jan; 191(2):239-52. PubMed ID: 10637269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.
    Yusim K; Kesmir C; Gaschen B; Addo MM; Altfeld M; Brunak S; Chigaev A; Detours V; Korber BT
    J Virol; 2002 Sep; 76(17):8757-68. PubMed ID: 12163596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.